I don't see yet what moved this one today. Nor am I sure

New Post Public Reply Private Reply Replies (1) Message Board
PoemStone znewcar1 #215
1,269
I don't see yet what moved this one today.
Nor am I sure what is the status of the cease order.

*** It reads below that USRM is still doing treatments but using other tissue
than their adipose fat the court and FDA have stopped
< >

Judge orders stem cell company to stop selling treatment
By William Wan June 25

A federal judge issued an order Tuesday barring a Florida-based stem-cell company from performing an unapproved procedure that blinded at least four patients.

The 16-page injunction from Judge Ursula Ungaro prevents U.S. Stem Cell Clinic from selling a scientifically unproven procedure that uses patients’ fat to create a stem cell treatment. The order spells out hefty financial fines if the company attempts to do so.

The order comes three weeks after the judge ruled against the company and in favor of the U.S. Food and Drug Administration, which has ramped up its efforts in the past year to rein in the booming and lucrative stem-cell industry.

It is unclear, however, whether the judge’s order — which is narrowly confined to the one company — will lead other stem-cell clinics to stop the practice. In recent years, the fat-based treatment has become widespread since it relies on a liposuction procedure already routinely performed by many cosmetic clinics that have added stem-cell treatments to their offerings.

Scientists, medical associations and health officials have long criticized stem-cell clinics for selling treatments unproved by science and unapproved by government regulators for a wide spectrum of unrelated ailments, such as Parkinson’s disease, multiple sclerosis, joint pain and erectile dysfunction.

In a statement, the FDA said, “Today’s action by Judge Ungaro is significant and sends a strong message to others manufacturing violative stem cell products. Court decisions like this reaffirm the FDA’s compliance and enforcement efforts in the ongoing fight to protect the public from individuals and clinics who mislead patients with unapproved and potentially harmful medical products.”

U.S. Stem Cell representatives said they are considering their legal options, including whether to appeal. In a statement, the company said, “We’re pleased to see the judge agreed with our position, limiting the injunction only to the SVF [fat-based stem cell] procedure.”

As FDA officials have increasingly cracked down on such companies, many have adapted quickly to attempt to circumvent regulators. Some have changed their marketing language and treatment protocols. Others have shuttered their operations, only to reopen them months later under a different name or location. A few have moved part of their operations overseas.

The judge’s injunction includes directives that appear to discourage such tactics. An independent expert is supposed to “conduct audit inspections” of U.S. Stem Cell’s facilities to make sure the company and people associated with it don’t resume the practice. The company can be fined $15,000 for each day it violates the order.

*** In recent weeks, U.S. Stem Cell said it has stopped selling the fat-based treatment, but company representatives have also made clear they intend to continue selling variations of the stem-cell treatment — using bone marrow and birth-related tissue — that are also unproven and unapproved but are not barred by the court order.

On its website Tuesday, the company was offering those stem-cell treatments to patients alongside other unproven treatments such as “acoustic wave” and “electromagnetic pulsed wave therapy.”

For many years, the FDA largely ignored the industry even as it grew rapidly. In 2017, the agency told businesses it would give them a three-year grace period during which businesses could work with the FDA to comply with laws and the FDA would only go after clinics offering the riskiest treatments. That grace period ends in 2020.

In Tuesday’s statement, FDA officials acknowledged that very few businesses have contacted them during the grace period to comply with the law. “The pace . . . has been slower than expected,” the agency said. “We know that there are clinics across the country that manufacture or market violative stem cell products to patients. . . . There are many examples of companies deceiving patients with unsubstantiated claims about the potential for stem cell products to prevent, treat or cure serious diseases, and in those cases we are committed to acting to protect patients.”

Agency officials said they are picking up enforcement actions and have sent regulatory letters or warnings to 46 businesses in the past year. But according to experts tracking the industry, there are more than a thousand such businesses now operating.

Laurie McGinley and Julie Tate contributed to this report.

Read more

Stem cell clinics likely to flourish despite judge’s rebuke

‘Miraculous’ stem cell therapy has sickened people in five states

This clinic’s experimental stem cell treatment blinded patients. Years later, the government is still trying to stop it.

U.S. Stem Cell, Inc. (USRM) Stock Research Links

USRM Board Company Profile Buy Rating Time & Sales News Filings Financials
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 18

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 30

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 26

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 29

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading
Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 17

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 28

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 25

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading

Top 5 Most Recently Viewed Articles

MarketWise's Strategic Position: Navigating Challenges Ahead

Updated Category News Views 123

MarketWise, Inc. (NASDAQ:MKTW) faced a rocky road since its SPAC merger back in July 2021. After initial pandemic-fueled growth due to retail investors diving into the market, the winds changed. Now, MarketWise's struggling under a mix of management shakeups and an unforgiving economic environment. Understanding MarketWise's Value Proposition The company's core business...

Continue Reading
NTT Emphasizes AI Cloud Development at R&D Forum 2024

Updated Category News Views 219

NTT's Commitment to Industry-Specific AI Solutions NTT Corporation hosted a groundbreaking forum in Tokyo to highlight its commitment to innovative solutions. This year’s R&D Forum showcased NTT's dedication to creating a sustainable society through the effective use of AI technology. During the event, NTT President and CEO Akira Shimada discussed the Innovative Optical...

Continue Reading
Oculis Enhances Financial Flexibility with Expanded Loan Facility

Updated Category News Views 146

Oculis Enhances Financial Flexibility with Expanded Loan Facility Oculis Holding AG (Nasdaq: OCS; Iceland: OCS) has made a strategic move to bolster its financial resources. The biopharmaceutical company, dedicated to addressing critical unmet medical needs in ophthalmology and neuro-ophthalmology, revealed they have entered into an amended loan agreement with BlackRock....

Continue Reading
Abbott's New Glucose Monitor: A Game Changer for Consumers

Updated Category News Views 85

Abbott Launches Innovative Glucose Monitoring Solution Abbott has recently made a significant impact in the health technology field with the introduction of its eagerly awaited over-the-counter continuous glucose monitoring system called Lingo, now available in the United States. This state-of-the-art device is specifically designed for consumers aged 18 and older who do...

Continue Reading
Longshot Partners with Mettle Ops in SHIELD Contract Win

Updated Category News Views 154

Longshot and Mettle Ops Join Forces in a Major Contract Longshot, a prominent defense and space technology firm, has joined the Mettle Ops team to secure a position on the Missile Defense Agency's (MDA) prestigious Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) Indefinite Delivery/Indefinite Quantity (IDIQ) contract. This contract opens exciting...

Continue Reading